How Epstein-Barr Virus May Trigger Multiple Sclerosis - an Updated Look

The original 2006 Brain paper reported that T cells responding to EBV nuclear antigen 1 (EBNA1) were more numerous and proliferative in MS patients than in EBV-infected healthy controls. Since then, large studies have strengthened the association between EBV infection and MS, and clinical success with B-cell-depleting therapies supports a role for EBV-harboring B cells in disease. EBV vaccines and approaches to remove EBV-infected cells are active research areas, but causal details and preventive interventions are not yet settled.

Summary of the 2006 finding

A 2006 study in Brain reported that people with multiple sclerosis (MS) carry an expanded population of T cells that respond strongly to Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1). The authors proposed that an unusually vigorous EBNA1-specific T-cell response could help trigger or worsen the autoimmune attack on the nervous system. That study compared untreated MS patients and EBV-infected healthy volunteers and found more numerous and more proliferative EBNA1-reactive T cells in the MS group, while responses to other viral and control antigens were normal.

What we know now

Since 2006, evidence linking EBV and MS has strengthened. Large longitudinal studies have shown that EBV infection precedes almost all cases of MS, and the risk of MS rises after primary EBV infection. At the same time, researchers have pursued mechanisms that could connect a ubiquitous virus to a rare autoimmune disease. Two leading ideas are:

• EBV-infected B cells provide a reservoir of abnormal antigen presentation and immune activation in the central nervous system.

• Cross-reactivity (molecular mimicry) between EBV proteins and components of myelin or other CNS proteins drives autoreactive immune responses.

Clinical implications and therapies

The link between EBV and MS has practical implications. B-cell-targeting therapies (for example, anti-CD20 monoclonal antibodies such as ocrelizumab and ofatumumab) reduce disease activity in many people with MS, which supports a role for B cells in disease pathogenesis. Because EBV persists in B cells, these treatments may act in part by removing EBV-harboring cells.

Vaccine development against EBV and strategies to eliminate EBV-infected B cells are active areas of research. An effective EBV vaccine could, in principle, reduce MS incidence, but no licensed EBV vaccine exists yet and clinical trials are still ongoing.

Open questions

Key questions remain. We still need to establish which specific antigenic targets and immune cell interactions drive MS in most patients, how EBV-related responses differ from normal antiviral immunity, and whether preventing EBV infection or selectively removing EBV-infected cells will lower MS risk.

Takeaway

The 2006 Brain study provided an early mechanistic clue - expanded, hyperproliferative EBNA1-reactive T cells in MS - that fits into a larger, evolving body of evidence implicating EBV in MS. That body of work has shifted MS research and treatment toward B-cell biology and renewed interest in EBV-directed prevention and therapies, but definitive causal mechanisms and preventive interventions are still under active investigation.